Platinum and taxane have significant activity as key drugs in current treatment of advanced ovarian cancer. While myelodysplastic syndrome (MDS) and acute leukemia are wellknown secondary disease after administration of chemotherapy, particularly with alkylating agents, they have only rarely been reported in the context of ovarian cancer treatment. In this case report a 59-year-old Japanese developed a MSD during ongoing second induction chemotherapy with carboplatin and paclitaxel for recurrent ovarian cancer. Her second induction began 9 months after completion of her first course of chemotherapy. Cytogenetic analyses showed typical chromosomal aberration. Although the finding of pancytopenia is also seen during chemotherapy without MSD/acute leukemia, bone marrow aspiration and biopsy should be considered to confirm the clinical suspicion of the lifethreatening disease when encountered persistent pancytopenia following carboplatin and paclitaxel-based chemotherapy in an ovarian cancer patient.
Cite this paper
Takagi, H. , Ichigo, S. , Matsunami, K. , Takagi, H. , Ikeda, T. , Murase, T. and Imai, A. (2013) Occurrence of myelodysplastic syndrome during paclitaxel- and carboplatin-based chemotherapy for recurrent ovarian cancer: Case report. Open Journal of Obstetrics and Gynecology, 3, 232-234. doi: 10.4236/ojog.2013.32043.
 Guastalla, J. and Diéras, V. (2003) The taxanes: Toxicity and quality of life considerations in advanced ovarian cancer. British Journal of Cancer, 89, S16-S22.
 Hagiwara, H. and Sunada, Y. (2004) Mechanism of taxane neurotoxicity. Breast Cancer, 11, 82-85.
 Smith, S., Le Beau, M., Huo, D., Karrison, T., Sobecks, R., Anastasi, J., Vardiman, J., Rowley, J. and Larson, R. (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: The University of Chicago series. Blood, 102, 43-52.
 Tam, C., Seymour, J., Prince, H., Kenealy, M., Wolf, M., Januszewicz, E. and Westerman, D. (2006) Treatmentrelated myelodysplasia following fludarabine combination chemotherapy. Haematologica, 91, 1546-1450.
 Whang-Peng, J., Young, R., Lee, E., Longo, D., Schechter, G. and De Vita, V.J. (1988) Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood, 71, 403-414.
 Armitage, J., Carbone, P., Connors, J., Levine, A., Bennett, J. and Kroll, S. (2003) Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. Journal of Clinical Oncology, 21, 897-906.
 Abe, A., Ikawa, H., Muguruma, H. and Maeda, Y. (2008) Secondary myelodysplasia and leukemia following carboplatin and paclitaxel-containing chemotherapy for ovarian cancer. (Article in Japanese), Gan To Kagaku Ryoho, 35, 1795-1798.
 Yeasmin, S., Nakayama, K., Ishibashi, M., Oride, A., Katagiri, A., Purwana, I., Iida, K., Nakayama, N., Ishikura, H. and Miyazaki, K. (2008) Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxeland carboplatin-based chemotherapy in an ovarian cancer patient: A case report and literature review. International Journal of Gynecologic Cancer, 18, 1371-1376.
 Perry, J., Brown, M. and Gockerman, J. (1998) Acute leukemia following treatment of malignant glioma. Journal of Neurooncology, 40, 39-46.
 Noronha, V., Berliner, N., Ballen, K., Lacy, J., Kracher, J., Baehring, J. and Henson, J. (2006) Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: Case study and review of the literature. Neurological Oncology, 8, 280-283.
 Jager, G., Hofler, G., Linkesch, W. and Neumeister, P. (2004) Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica, 89, ECR1-3.?